A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.

@article{Henry2013ARO,
  title={A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.},
  author={Robert R. Henry and Douglas Logan and Thomas R. Alessi and Michelle A Baron},
  journal={Clinical therapeutics},
  year={2013},
  volume={35 5},
  pages={
          634-645.e1
        }
}
BACKGROUND Exenatide, a glucagon-like peptide-1 receptor agonist administered by self-injection, decreases plasma glucose, glycosylated hemoglobin (HbA1c), and weight in patients with type 2 diabetes. ITCA 650 is an investigational new drug that provides continuous subcutaneous delivery of exenatide. OBJECTIVE This randomized, open-label, multicenter, 28-day study evaluated the tolerability, pharmacodynamics, and pharmacokinetics of ITCA 650 in patients with type 2 diabetes. METHODS The… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

ITCA 650

  • Clinical diabetes : a publication of the American Diabetes Association
  • 2018
VIEW 1 EXCERPT

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.

  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2011

Pharmacokinetics and pharmacodynamics of exenatide extended - release after single and multiple dos

K Gurney, J Han
  • Clin Pharmacokinet
  • 2011